Endnotes


 

Return to Contents

 

Transforming institutions
As I finished writing about Shannon Faulkner’s fight against the Citadel, there came a point when I realized it’s not integration but transformation that is necessary for the most traditional of our institutions to genuinely move forward. Though we are still wedded to the rhetoric of integration of women in the workplace, we really must talk about transforming these institutions in a way that will accommodate both fathers and mothers, for instance, as well as genuinely different styles of leadership. Some institutions are going to be harder to transform than others. The military is a great example. And the press is not that different from the military, in certain respects. But transformation demands a lot more intelligence and persistence of approach because it's easier to stay with the old language. The fact is, integration has already happened. We now have to find a much more nuanced and shaded path to achieve a new level of cultural growth.

—Catherine Manegold, Cox Professor of Journalism and author of In Glory’s Shadow: The Citadel, Shannon Faulkner, and a Changing America, speaking as part of a Feminist Publishing Series sponsored by Women's Studies on March 8, 2002



The immortal stem cell

The advantages of human embryonic stem cells are many. They are immortal—they can go on forever. They are flexible, meaning they can make any of the tissue types in the body. And although it is always a controversial issue, they are available. Human embryos are available because of in vitro fertilization. Often many more embryos are made than are needed for a couple to produce a family. Many of those are just frozen in liquid nitrogen and stored. And there are a number of those that are deformed and do not have the capability of developing into a fetus or an individual.
In Athens, the four embryonic cell lines we have all came from a fertility clinic we work with. They came from embryos that were thought to be non-viable and were going to be trashed. We were quite pleased that we were able to grow those into embryonic stem cells that have all the characteristics of those derived at the University of Wisconsin.

—Steven Stice, professor at the University of Georgia and vice president for human stem cell research at BresaGen, which has four of the human embryonic stem cell lines approved for NIH funding. Stice spoke at the Biochemistry, Cell, and Molecular Biology Symposium, April 5, 2002.